Virtu KCG Holdings’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Virtu KCG Holdings’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$72K	Buy	+47,932	New	+$103K	﹤0.01%	2510
2017 Q1	–	Sell	-12,713	Closed	-$32K	–	4059
2016 Q4	$32K	Sell	12,713 -44,908	-78%	-$129K	﹤0.01%	3178
2016 Q3	$178K	Buy	57,621 +31,441	+120%	+$98K	﹤0.01%	2424
2016 Q2	$84K	Buy	26,180 +11,081	+73%	+$40.6K	﹤0.01%	2576
2016 Q1	$47K	Sell	15,099 -1,574	-9%	-$5.14K	﹤0.01%	2473
2015 Q4	$67K	Buy	16,673 +6,478	+64%	+$29.8K	﹤0.01%	3099
2015 Q3	$47K	Sell	10,195 -18,425	-64%	-$96.4K	﹤0.01%	3007
2015 Q2	$149K	Buy	+28,620	New	+$172K	﹤0.01%	2754
2015 Q1	–	Sell	-10,502	Closed	-$66K	–	4192
2014 Q4	$66K	Sell	10,502 -5,063	-33%	-$30.9K	﹤0.01%	3360
2014 Q3	$94K	Buy	+15,565	New	+$106K	﹤0.01%	3202
2014 Q2	–	Sell	-12,660	Closed	-$301K	–	4235
2014 Q1	$301K	Buy	+12,660	New	+$184K	﹤0.01%	2514

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

CRC

Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Virtu KCG Holdings's ECYT Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Endocyte, Inc. Common Stock (ECYT) in Q2 2017: 47,932 shares worth $72K. The stake represents ﹤0.01% of the portfolio and ranks #2510 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in ECYT as recently as Q4 2016.

Virtu KCG Holdings first reported a position in ECYT in Q1 2014 and has held it in 11 quarters since. The position peaked at $301K in Q1 2014. 75 funds tracked by Wall St. Rank hold ECYT as of Q2 2017.

Virtu KCG Holdings held 47,932 shares of Endocyte, Inc. Common Stock worth $72K as of Q2 2017.
Endocyte, Inc. Common Stock was a new Virtu KCG Holdings position in Q2 2017.
Endocyte, Inc. Common Stock made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2510 holding.
Virtu KCG Holdings first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and has held it in 11 quarters since.
Virtu KCG Holdings's Endocyte, Inc. Common Stock position peaked at $301K in Q1 2014.
75 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.